BOYDSense SAS, a subsidiary of Alpha MOS, develops a miniaturized respiratory analysis platform to monitor chronic diseases with a first diabetes monitoring application.
FREMONT, CA: BOYDSense SAS, a subsidiary of Alpha MOS (ALM), starts a miniature respiratory analysis platform for monitoring chronic diseases, focusing on diabetes. Additionally, BOYDSense elects Ben Delhey as an independent Supervisory Board member.
Ben Delhey has over 15 years of experience in senior management in the healthcare industry. He has worked for several leading diabetes medical technology and pharmaceutical companies, including LifeScan, Ascencia, and Sanofi. In addition, Ben Delhey is a pharmaceutical device launch specialist. He has launched over ten diabetes devices and software as medical devices distributed in over 25 countries worldwide throughout his sales and marketing career. These high-profile devices include the OneTouch® Vita®, Sanofi's MyStar®, and Mhealth Software's My Dose Coach®.
“I am very excited to join the BOYDSense team. We are starting a new era in terms of technologies applied to diabetes. The last few years have been really interesting with the release of brand-new innovations. The BOYDSense device will drastically improve the way patients with diabetes will measure their blood glucose level. This is great news for patients with diabetes, because this innovation will greatly facilitate their daily life and allow them to monitor their glucose levels in a more gentle way.” comments Ben Delhey.
Anton Kittelberger, Chairman of the Supervisory Board of BOYDSense, adds, “Ben is the perfect addition to our team. He will bring us his huge experience in terms of diabetes, acces to the market and launching of medical devices. We are very confident because Ben has already done all these missions for Sanofi, Bayer or Johnson & Johnson. We are really looking forward to working together on our next succes.”